Kathmere Capital Management, LLC Biogen Inc. Transaction History

Kathmere Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 01, 2024	BUY	$190.52 - $236.72 $156,226 - $194,110	820 New	820 $190,000
Q1 2024 Apr 16, 2024	SELL	$212.02 - $267.71 $173,856 - $219,522	-820 Closed	0 $0
Q4 2023 Apr 16, 2024	SELL	$222.59 - $267.94 $19,365 - $23,310	-87 Reduced 9.59%	820 $212,000
Q2 2023 Jul 11, 2023	BUY	$275.25 - $318.06 $249,651 - $288,480	907 New	907 $258,000
Q1 2021 May 07, 2021	SELL	$242.95 - $284.63 $87,947 - $103,036	-362 Closed	0 $0
Q3 2020 Nov 20, 2020	BUY	$264.77 - $305.71 $95,846 - $110,667	362 New	362 $103,000
Q1 2020 May 06, 2020	SELL	$268.85 - $341.04 $247,610 - $314,097	-921 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$220.06 - $304.07 $202,675 - $280,048	921 New	921 $273,000

1,037

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.6B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Kathmere Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Kathmere Capital Management, LLC with notifications on news.